The QR678 hair growth factor formulation has been found to be effective in treating pattern alopecia in women suffering from Polycystic Ovary Syndrome (PCOS), according to a prospective study by Dr. Debraj Shome, Celebrity Cosmetic Surgeon and Dr. Rinky Kapoor, a Dermatologist heading The Esthetic Clinics™ across India. QR678® hair growth therapy was invented by Dr. Shome and Dr. Kapoor.
The success of this study is a major breakthrough for the cosmetic beauty industry. Hair is an important feature of a woman’s personality and when hormonal imbalances lead to PCOS and its side-effects of hair loss along randomized hair growth on the body it takes a hard hit on the self-esteem, image, and confidence of a woman. Around 20-30% of the women with PCOS suffer from female pattern hair loss. Cosmetic surgeon and the brainchild behind the QR678, Dr. Debraj Shome also believes that “this opens up a brand new world for the field of cosmetology in India. This solves one of the many beauty related issues which will be a game-changer for the beauty industry for women.”
This study was conducted with the agenda of evaluating the efficiency of the QR678® and QR678 Neo® therapy for the cure of female alopecia and PCOS. Using a broad range method 20 women between 25 to 50 years of age with PCOS female patterns with Grade I & II Ludwig scale were chosen for the study. A solution of QR678® was administered in the scalp of the patient, with a 3-week interval between eight such sessions. Using standard global photography for evaluation marked improvement was noticed after eight sessions. The study showed the 20 women had 11.66 fewer vellus hair, 13.77 more terminal hair, and hair shaft diameter was 2.86 μm broader than at baseline. “This successful study has highlighted the potential for hair loss remedy for women suffering from PCOS. If further trials and consequent studies are successful we intend to create more awareness about the same in space of gynecology where PCOS and related issues are dealt with”, says Rinky Kapoor. This was the first study using QR678® and QR678 Neo® in patients suffering from PCOS.